PRI-VENT FSGS: Preemptive Rituximab to Prevent Recurrent Focal Segmental Glomerulosclerosis Post-Transplant
As far as I can find:
https://clinicaltrials.gov/study/NCT03763643
this is the only randomised trial underway due for completion in 2026 and this is for post transplant patients.
Ann: Investor Presentation, page-104
-
- There are more pages in this discussion • 73 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $242.2M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 45.0¢ | 44.0¢ | $365.3K | 823.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 46584 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.5¢ | 3953 | 1 |
View Market Depth
| Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
| DXB (ASX) Chart |